10X GENOMICS INC-CLASS A (TXG) Stock Analyst Ratings
USA - NASDAQ:TXG - US88025U1097 - Common Stock
13.77 USD
+0.41 (+3.07%)
13.77 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 73% to TXG. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 15.3. This target is 11.11% above the current price.
TXG was analyzed by 23 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about TXG.
In the previous month the buy percentage consensus was at a similar level.
TXG was analyzed by 23 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-11 | Piper Sandler | Initiate | Neutral |
| 2025-08-12 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-08 | UBS | Maintains | Neutral -> Neutral |
| 2025-08-08 | Barclays | Maintains | Overweight -> Overweight |
| 2025-06-26 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-06-24 | Barclays | Maintains | Overweight -> Overweight |
| 2025-05-19 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-05-15 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-05-13 | UBS | Maintains | Neutral -> Neutral |
| 2025-05-12 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-05-12 | Goldman Sachs | Maintains | Sell -> Sell |
| 2025-05-09 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-04-10 | Barclays | Maintains | Overweight -> Overweight |
| 2025-03-04 | Citigroup | Maintains | Buy -> Buy |
| 2025-02-14 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-14 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-02-13 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-02-13 | UBS | Maintains | Neutral -> Neutral |
| 2025-02-13 | Stifel | Maintains | Buy -> Buy |
| 2025-02-13 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-02-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-02-13 | Citigroup | Maintains | Buy -> Buy |
| 2025-02-10 | Barclays | Maintains | Overweight -> Overweight |
| 2025-01-13 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-11-01 | Barclays | Maintains | Overweight -> Overweight |
| 2024-10-30 | UBS | Maintains | Neutral -> Neutral |
| 2024-10-30 | JP Morgan | Maintains | Neutral -> Neutral |
| 2024-10-30 | Goldman Sachs | Maintains | Sell -> Sell |
| 2024-10-30 | Citigroup | Maintains | Buy -> Buy |
| 2024-10-15 | Barclays | Maintains | Overweight -> Overweight |
10X GENOMICS INC-CLASS A / TXG FAQ
Can you provide the average price target for 10X GENOMICS INC-CLASS A stock?
23 analysts have analysed TXG and the average price target is 15.3 USD. This implies a price increase of 11.11% is expected in the next year compared to the current price of 13.77.
Can you provide the consensus rating for 10X GENOMICS INC-CLASS A stock?
The consensus rating for 10X GENOMICS INC-CLASS A (TXG) is 73.0435 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover 10X GENOMICS INC-CLASS A (TXG) stock?
The number of analysts covering 10X GENOMICS INC-CLASS A (TXG) is 23.